BGM Group (BGM) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Jyong Biotech (MENS) has outperformed BGM Group (BGM) over the past year, losing 96.1% versus a loss of 96.3%. Jyong Biotech is the larger company by market cap ($159.7 million vs $143.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | MENS |
|---|---|---|
| Share price | $10.75 | $2.10 |
| Market cap | $143.56M | $159.66M |
| 1-day change | +10.94% | 0.00% |
| YTD return | -90.29% | -46.84% |
| 1-year return | -96.31% | -96.12% |
| 5-year return | -98.19% | — |
| EPS (TTM) | $-4.80 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $63.00 |
| 52-week low | $6.45 | $1.43 |
| Distance from 52-week high | -96.45% | -96.67% |
| Average volume | 6.11K | 45.61K |
| Shares outstanding | 12.69M | 74.23M |
| Employees | — | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
BGM vs MENS FAQ
Which is bigger, BGM Group or Jyong Biotech?
Jyong Biotech (MENS) is larger, with a market capitalization of $159.66M compared with $143.56M for BGM Group (BGM).
Which stock has performed better over the past year, BGM or MENS?
MENS returned -96.12% over the past 12 months, compared with -96.31% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.